PMID- 30476928
OWN - NLM
STAT- MEDLINE
DCOM- 20190503
LR  - 20190503
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 96
IP  - 4
DP  - 2019
TI  - Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in 
      Latin America.
PG  - 207-216
LID - 10.1159/000493733 [doi]
AB  - OBJECTIVE: Latin American countries are heterogeneous in terms of lung cancer 
      incidence and exposure to potential carcinogens. We evaluated the frequency and 
      clinical characteristics of ALK rearrangements (ALKr) in Latin America. METHODS: 
      A total of 5,130 lung cancer patients from 10 Latin American countries were 
      screened for inclusion. ALKr detection was performed by fluorescence in situ 
      hybridization (FISH), immunohistochemistry (IHC), and real-time reverse 
      transcriptase-polymerase chain reaction (RT-PCR) to assess method variability. 
      Demographic and clinicopathologic characteristics were analyzed. RESULTS: Among 
      the 5,130 patients screened, 8.4% (n = 433) had nonevaluable FISH tests. 
      Evaluable FISH analyses revealed positive ALKr in 6.8% (320/4,697) of the study 
      population, which included patients from 9 countries. ALKr distribution for each 
      country was: Mexico 7.6% (79/1,034), Colombia 4.1% (10/242), Argentina 6.0% 
      (153/2,534), Costa Rica 9.5% (13/137), Panama 4.4% (5/114), Uruguay 5.4% (2/37), 
      Chile 8.6% (16/185), Venezuela 8.9% (13/146), and Peru 10.8% (29/268). RT-PCR 
      showed high positive (83.6%) and negative (99.7%) predictive values when compared 
      to the gold standard FISH. In contrast, IHC only showed a high negative 
      predictive value (94.6%). CONCLUSIONS: Although there is a clear country and 
      continental variability in terms of ALKr frequency, this difference is not 
      significant and the overall incidence of ALKr in Latin America does not differ 
      from the rest of the world.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - Arrieta, Oscar
AU  - Arrieta O
AD  - Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, 
      Mexico, oscararrietaincan@gmail.com.
FAU - Cardona, Andres F
AU  - Cardona AF
AD  - Clinical and Translational Oncology Group, Institute of Oncology, Clinica del 
      Country, Bogota, Colombia.
AD  - Foundation for Clinical and Applied Cancer Research-FICMAC, Bogota, Colombia.
FAU - Bramuglia, Guillermo
AU  - Bramuglia G
AD  - Pharmacy and Biochemistry Faculty, Universidad de Buenos Aires, Buenos Aires, 
      Argentina.
AD  - Foundation "Investigar", Buenos Aires, Argentina.
FAU - Cruz-Rico, Graciela
AU  - Cruz-Rico G
AD  - Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, 
      Mexico.
FAU - Corrales, Luis
AU  - Corrales L
AD  - Medical Oncology Department, Hospital San Juan de Dios, San Jose, Costa Rica.
FAU - Martin, Claudio
AU  - Martin C
AD  - Medical Oncology Department, Thoracic Oncology Section, Instituto Fleming, Buenos 
      Aires, Argentina.
FAU - Imaz-Olguin, Victoria
AU  - Imaz-Olguin V
AD  - Oncologia Integral de Alta Especialidad, Hospital ABC, Mexico City, Mexico.
FAU - Castillo, Omar
AU  - Castillo O
AD  - Internal Medicine-Medical Oncology Department, National Institute of Cancer, 
      Panama City, Panama.
FAU - Cuello, Mauricio
AU  - Cuello M
AD  - Medical Oncology Department, Universidad de la Republica-UdeLAR, Montevideo, 
      Uruguay.
FAU - Rojas-Bilbao, Erica
AU  - Rojas-Bilbao E
AD  - Pathology Department, Instituto de Oncologia Angel H. Roffo, University of Buenos 
      Aires, Buenos Aires, Argentina.
FAU - Casas, Gabriel
AU  - Casas G
AD  - Pathology Department, Hospital Aleman, Buenos Aires, Argentina.
FAU - Fernandez, Cristina
AU  - Fernandez C
AD  - Pathology Department, Hospital Clinico de la Universidad de Chile, Santiago de 
      Chile, Chile.
FAU - Aren Frontera, Osvaldo
AU  - Aren Frontera O
AD  - Pathology Department, Hospital Clinico de la Universidad de Chile, Santiago de 
      Chile, Chile.
FAU - Denninghoff, Valeria
AU  - Denninghoff V
AD  - Centro de Estudios Medicos e Investigaciones Clinicas "Norberto Quirno" (CEMIC), 
      Buenos Aires, Argentina.
FAU - Recondo, Gonzalo
AU  - Recondo G
AD  - Centro de Estudios Medicos e Investigaciones Clinicas "Norberto Quirno" (CEMIC), 
      Buenos Aires, Argentina.
FAU - Aviles-Salas, Alejandro
AU  - Aviles-Salas A
AD  - Department of Pathology, Instituto Nacional de Cancerologia (INCan), Mexico City, 
      Mexico.
FAU - Mas-Lopez, Luis-Alberto
AU  - Mas-Lopez LA
AD  - Instituto Nacional de Enfermedades Neoplasicas, Surquillo, Peru.
FAU - Oblitas, George
AU  - Oblitas G
AD  - Medical Oncology Department, Thoracic Oncology Section, Instituto Oncologico "Dr. 
      Luis Razetti", Caracas, Venezuela.
FAU - Rojas, Leonardo
AU  - Rojas L
AD  - Oncology Department, Centro Javeriano de Oncologia, Hospital Universitario San 
      Ignacio, Bogota, Colombia.
FAU - Piottante, Antonio
AU  - Piottante A
AD  - Department of Pathology, Clinica las Condes, Santiago, Chile.
FAU - Jimenez-Garcia, Ernesto
AU  - Jimenez-Garcia E
AD  - Tecnicas Geneticas Aplicadas a la Clinica, Mexico City, Mexico.
FAU - Sanchez-Sosa, Sergio
AU  - Sanchez-Sosa S
AD  - Hospital Angeles de Puebla. Escuela de Medicina UDLAP (Universidad de las 
      Americas Puebla), Puebla, Mexico.
FAU - Saenz-Frias, Julia
AU  - Saenz-Frias J
AD  - Centro Medico del Noreste, Unidad Medica de Alta Especialidad UMAE, Instituto 
      Mexicano del Seguro Social, Monterrey, Mexico.
FAU - Lupera, Hernan
AU  - Lupera H
AD  - Department of Pathology, Hospital Metropolitano, Guayaquil, Ecuador.
FAU - Ramirez-Tirado, Laura Alejandra
AU  - Ramirez-Tirado LA
AD  - Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, 
      Mexico.
FAU - Vargas, Carlos
AU  - Vargas C
AD  - Clinical and Translational Oncology Group, Institute of Oncology, Clinica del 
      Country, Bogota, Colombia.
FAU - Carranza, Hernan
AU  - Carranza H
AD  - Clinical and Translational Oncology Group, Institute of Oncology, Clinica del 
      Country, Bogota, Colombia.
FAU - Astudillo, Horacio
AU  - Astudillo H
AD  - Consejo de Nanopharmacia Diagnostica, Mexico City, Mexico.
FAU - Wills, Laura Beatriz
AU  - Wills LB
AD  - Foundation for Clinical and Applied Cancer Research-FICMAC, Bogota, Colombia.
FAU - Pichelbaur, Ernestina
AU  - Pichelbaur E
AD  - Pharmacy and Biochemistry Faculty, Universidad de Buenos Aires, Buenos Aires, 
      Argentina.
FAU - Raez, Luis E
AU  - Raez LE
AD  - Memorial Cancer Institute, Memorial Healthcare System, Hollywood, Florida, USA.
CN  - on behalf of the CLICaP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20181126
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
SB  - IM
MH  - Adenocarcinoma of Lung/diagnosis/*epidemiology/*genetics
MH  - Aged
MH  - Anaplastic Lymphoma Kinase/*genetics
MH  - Biomarkers, Tumor/*genetics
MH  - Female
MH  - *Gene Rearrangement
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Incidence
MH  - Latin America/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Molecular Epidemiology
MH  - Prevalence
MH  - Real-Time Polymerase Chain Reaction
MH  - Retrospective Studies
MH  - Reverse Transcriptase Polymerase Chain Reaction
OTO - NOTNLM
OT  - ALK
OT  - FISH
OT  - Latin America
OT  - Non-small-cell lung cancer
OT  - Rearrangements
EDAT- 2018/11/27 06:00
MHDA- 2019/05/06 06:00
CRDT- 2018/11/27 06:00
PHST- 2018/04/17 00:00 [received]
PHST- 2018/09/12 00:00 [accepted]
PHST- 2018/11/27 06:00 [pubmed]
PHST- 2019/05/06 06:00 [medline]
PHST- 2018/11/27 06:00 [entrez]
AID - 000493733 [pii]
AID - 10.1159/000493733 [doi]
PST - ppublish
SO  - Oncology. 2019;96(4):207-216. doi: 10.1159/000493733. Epub 2018 Nov 26.